Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Whitehawk Therapeutics Q3 2026 Results: Net Loss of $21.2M, Loss Widens

Whitehawk Therapeutics reported a net loss of $60.0 million for the nine months ended September 30, 2026, compared to a net income of $2.7 million in the prior year period, which had been bolstered by an $87.3 million gain on the sale of a business. The company ended the quarter with $169.7 million in cash, cash equivalents, and short-term investments following a private placement that raised approximately $81.7 million in net proceeds.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Profit before tax-21.2-17.7
Net income-21.2-17.7
EPS (diluted, $ a share)$-0.23$-0.26

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: WHWK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Whitehawk Therapeutics, Inc.: key numbers

Share price
$3.01Close, Nov 16
Market cap
$178M
Shares outstanding
59.01MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Whitehawk Therapeutics, Inc.

All →
8:05 AM ET 8-K
Financial Results

Whitehawk Therapeutics Financial Results

Whitehawk Therapeutics reported third quarter 2026 financial results, ending the period with $169.7 million in cash which is expected to fund operations into the second half of 2028. The company highlighted the initiation of its Phase 1 trial for HWK-206 and remains on track to report initial data from its HWK-007 and HWK-016 programs in the first half of 2027.

“We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027. We also initiated the Phase 1 trial of HWK-206, marking the advancement of all three of our original ADC programs into clinical development within the last 12 months.”

Dave Lennon, PhD, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.